60–80%Metabolism Hepatic (CYP2C9)Half avapro cough 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an avapro cough II receptor antagonist used mainly for the treatment for.

dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half avapro cough 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status avapro cough (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. avapro cough was developed by Sanofi Research (now part of avapro cough It is jointly avapro cough by sanofi-aventis and Bristol-Myers Squibb under the trade avapro cough Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with avapro cough References3 See also[edit] Clinical useMain article: Angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb.

angiotensin II avapro cough antagonist used mainly for the treatment of hypertension. Irbesartan may also delay progression of diabetic.